Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | NOS1 | P29475 | 2/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | S100A4 | P26447 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.37 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL835945 | 0.71 | TDP1 (0.44) | TDP1NOS1GPR35ALDH1A1TSHR | |
| SCHEMBL647458 | 0.70 | NOS1 (0.50) | TDP1NOS1GPR35ALDH1A1TSHR | |
| SCHEMBL6030727 | 0.69 | TDP1 (0.48) | TDP1NOS1GPR35ALDH1A1TSHR | |
| SCHEMBL6007713 | 0.67 | TDP1 (0.52) | TDP1NOS1GPR35ALDH1A1TSHR | |
| SCHEMBL1966793 | 0.67 | FFAR1 (0.41) | — | |
| SCHEMBL321694 | 0.67 | GPR84 (0.41) | NOS1TSHRCYP1A2GAA | |
| SCHEMBL28549 | 0.67 | ALDH1A1 (0.64) | TDP1NOS1GPR35ALDH1A1TSHR | |
| SCHEMBL29471420 | 0.67 | ALDH1A1 (0.64) | TDP1NOS1GPR35ALDH1A1TSHR | |
| SCHEMBL643696 | 0.67 | ALDH1A1 (0.50) | TDP1NOS1GPR35ALDH1A1TSHR | |
| SCHEMBL647821 | 0.66 | TDP1 (0.55) | TDP1NOS1GPR35ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3323816-B1 | NOVEL PYRAZOLE DERIVATIVE | GREEN TECHNOLOGY CO LTD (JP) | 2019-07-03 | — | — | EP | claimed |
| EP-3323816-A1 | NOVEL PYRAZOLE DERIVATIVE | Green Tech Co., Ltd. (JP) | 2018-05-23 | — | — | EP | claimed |
| US-9399635-B2 | Pyrazole derivative | GREEN TECH CO., LTD. (JP) | 2016-07-26 | — | — | US | claimed |
| US-8962674-B2 | Curcumin derivative | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2015-02-24 | — | — | US | claimed |
| US-20140088029-A1 | NOVEL PYRAZOLE DERIVATIVE | PHARMA EIGHT CO., LTD. (JP) | 2014-03-27 | — | — | US | claimed |
| EP-2698368-A1 | NOVEL PYRAZOLE DERIVATIVE | Pharma Eight Co. Ltd (JP) | 2014-02-19 | — | — | EP | claimed |
| US-20100048901-A1 | NOVEL CURCUMIN DERIVATIVE | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2010-02-25 | — | — | US | claimed |
| EP-2123637-A1 | NOVEL CURCUMIN DERIVATIVE | Tokyo Institute of Technology (JP) | 2009-11-25 | — | — | EP | claimed |
| CN-101558038-A | Novel curcumin derivative | TOKYO INST TECH (JP) | 2009-10-14 | — | — | CN | claimed |
| CN-117402829-A | Dual control for therapeutic cell activation or elimination | 贝里坤制药股份有限公司 | 2024-01-16 | — | — | CN | disclosed |
| WO-2022258057-A1 | COMPOUNDS AS ANTICANCER AGENTS | JINGRUI BIOPHARMA CO., LTD. (CN) | 2022-12-15 | — | — | WO | disclosed |
| US-11208662-B2 | RNAi inhibition of alpha-ENaC expression | Arrowhead Pharmaceuticals, Inc. (US) | 2021-12-28 | — | — | US | disclosed |
| WO-2021006267-A1 | SALT OF PYRAZOLE DERIVATIVE AND PREPARATION OF PYRAZOLE DERIVATIVE | グリーン・テック株式会社 | 2021-01-14 | — | — | WO | disclosed |
| WO-2020235582-A1 | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR MOTOR NEURON DISEASE | グリーン・テック株式会社 (JP) | 2020-11-26 | — | — | WO | disclosed |
| US-20070054279-A1 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS (US) | 2007-03-08 | — | — | US | disclosed |
| WO-2006112872-A2 | OLIGONUCLEOTIDES COMPRISING A LIGAND TETHERED TO A MODIFIED OR NON-NATURAL NUCLEOBASE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006093526-A2 | OLIGONUCLEOTIDES COMPRISING A MODIFIED OR NON-NATURAL NUCLEOBASE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20060035254-A1 | Oligonucleotides comprising a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | US | disclosed |
| US-6074638-A | APPLYING A SUPPRESSIVE DOSAGE STRAIN OF STREPTOMYCES | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2000-06-13 | — | — | US | disclosed |
| WO-1994027443-A1 | COMPOSITION AND METHOD FOR INHIBITING PLANT DISEASE | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1994-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048901-A1 | NOVEL CURCUMIN DERIVATIVE | BACE1, APP, BACE2 | TDP1 1738/4885NOS1 304/4885GPR35 4160/4885 |
| US-20140088029-A1 | NOVEL PYRAZOLE DERIVATIVE | PSEN2, MAPT, PSEN1 | TDP1 561/4885NOS1 1380/4885GPR35 691/4885 |
| US-20070054279-A1 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | DERA, NT5C3B, DUT | TDP1 1435/4885NOS1 3901/4885GPR35 697/4885 |
| US-20060035254-A1 | Oligonucleotides comprising a modified or non-natural nucleobase | NT5C3B, DERA, DUT | TDP1 672/4885NOS1 2040/4885GPR35 1559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.